213 related articles for article (PubMed ID: 21831721)
1. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.
De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A
Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721
[TBL] [Abstract][Full Text] [Related]
2. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
3. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
[TBL] [Abstract][Full Text] [Related]
6. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
8. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
Murphy C; Mukaro V; Tobler R; Asher R; Gibbs E; West L; Giuffre B; Baron-Hay S; Khasraw M
Intern Med J; 2018 Jun; 48(6):699-705. PubMed ID: 28869790
[TBL] [Abstract][Full Text] [Related]
10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
11. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
[TBL] [Abstract][Full Text] [Related]
13. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy.
Williams M; Eatrides J; Kim J; Talwar H; Esposito N; Szabunio M; Ismail-Khan R; Kiluk J; Lee M; Laronga C; Khakpour N
Am J Surg; 2013 Oct; 206(4):567-73. PubMed ID: 23809673
[TBL] [Abstract][Full Text] [Related]
14. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
15. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients].
Zhou YJ; Ying M; He YJ; Liu YQ; Fan ZQ; Fan T; Li JF; Wang TF; Xie YT; Lu AP; Ouyang T
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1711-5. PubMed ID: 24124677
[TBL] [Abstract][Full Text] [Related]
17. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
Javid S; Segara D; Lotfi P; Raza S; Golshan M
Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
[TBL] [Abstract][Full Text] [Related]
19. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
20. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]